9 First Eagle Investments Bio-Rad Laboratories Trades
First Eagle Investments's position in Bio-Rad Laboratories is currently worth $744M. The stake costed the investor $692M, netting the investor a gain of 7.5% so far.
Avg closing price
Price range
Increased shares by 60.7% (+951k shares)
Q2 2025
Avg closing price
$236.19
Price range
$216.56
-
$256.68
Increased shares by 119.5% (+853k shares)
Q1 2025
Avg closing price
$301.86
Price range
$243.00
-
$366.66
Increased shares by 0.1% (+505 shares)
Q4 2024
Avg closing price
$339.22
Price range
$313.10
-
$374.01
Increased shares by 12.1% (+76.7k shares)
Q3 2024
Avg closing price
$317.17
Price range
$263.97
-
$344.60
Increased shares by 32296.9% (+634k shares)
Q2 2024
Avg closing price
$290.85
Price range
$268.26
-
$339.48
Increased shares by 310.0% (+1.49k shares)
Q1 2024
Avg closing price
$328.84
Price range
$304.11
-
$351.99
Increased shares by 4.6% (+21 shares)
Q4 2023
Avg closing price
$313.43
Price range
$269.37
-
$365.04
Increased shares by 139.8% (+267 shares)
Q3 2023
Avg closing price
$385.83
Price range
$350.25
-
$422.63
New holding (+191 shares)
Q2 2023
Avg closing price
$406.95
Price range
$359.49
-
$486.40
News about Bio-Rad Laboratories Inc. - Ordinary Shares - Class A and First Eagle Investments
North America Antinuclear Antibody Test Market 2021: Industry Updates Future Growth, Business Prospects, Forthcoming Developments and Future Investments, Prominent Players - Bio-Rad Laboratories, Antibodies, Inc, Euroimmun AG by Forecast to 2027
Antinuclear Antibody Test Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outs...